➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
AstraZeneca
Baxter
Boehringer Ingelheim
Johnson and Johnson

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SELUMETINIB SULFATE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Selumetinib Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01085214 ↗ AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma Completed National Cancer Institute (NCI) Phase 2 2010-03-01 This phase II trial studies how well selumetinib works in treating patients with multiple myeloma, a type of cancer in which a specific protein is over active. Selumetinib may stop the growth of cancer cells by blocking this protein.
NCT01116271 ↗ Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec Completed AstraZeneca Phase 2 2010-04-01 The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.
NCT01166126 ↗ Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV Terminated National Cancer Institute (NCI) Phase 2 2010-10-01 The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma
NCT01278615 ↗ Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Terminated National Cancer Institute (NCI) Phase 2 2010-12-01 This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT01362803 ↗ AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2011-05-01 Background: - Plexiform neurofibromas are tumors that grow in and around nerves. The only way to treat them is with surgery. Some of these tumors cannot be completely removed. The tumors may be too large, too numerous, or in a bad location for surgery. An experimental drug called AZD6244 hydrogen sulfate may be able to prevent the tumors from growing, slow down their growth, or shrink them. This drug has been tested in adults with cancer and in children with some types of brain cancer. This study will test how well this drug works with these types of tumors. Objectives: - To study the safety and effectiveness of AZD6244 hydrogen sulfate in children and young adults with plexiform neurofibromas that cannot be completely removed by surgery. Eligibility: - Children and young adults between 12 and 18 years of age who have plexiform neurofibromas that cannot be completely removed by surgery. Design: - Patients will be screened with a physical exam, medical history, blood tests, and imaging studies. - They will take the study drug twice a day with 8 ounces of water, every day for 28-day cycles of treatment. During study visits, participants will have blood and urine tests and physical exams. They will also have imaging studies to examine the tumor sizes and locations. They will answer questions about their health. They may have other tests as needed. - Participants will continue to receive the study drug as long as they have no severe side effects and the disease is not getting worse.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selumetinib Sulfate

Condition Name

Condition Name for Selumetinib Sulfate
Intervention Trials
Solid Tumours 5
Neurofibromatosis Type 1 4
Neurofibromatosis 1 3
Low Grade Glioma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Selumetinib Sulfate
Intervention Trials
Neurofibroma 6
Neurofibromatosis 1 6
Neurofibromatoses 6
Nerve Sheath Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Selumetinib Sulfate

Trials by Country

Trials by Country for Selumetinib Sulfate
Location Trials
United States 134
Canada 10
United Kingdom 4
Germany 3
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Selumetinib Sulfate
Location Trials
Maryland 9
Pennsylvania 9
Florida 9
New York 7
California 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Selumetinib Sulfate

Clinical Trial Phase

Clinical Trial Phase for Selumetinib Sulfate
Clinical Trial Phase Trials
Phase 3 5
Phase 2 14
Phase 1/Phase 2 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Selumetinib Sulfate
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 8
Recruiting 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Selumetinib Sulfate

Sponsor Name

Sponsor Name for Selumetinib Sulfate
Sponsor Trials
National Cancer Institute (NCI) 18
AstraZeneca 15
Melanoma Research Alliance 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Selumetinib Sulfate
Sponsor Trials
NIH 18
Industry 15
Other 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Harvard Business School
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.